Shares of Inovio Pharmaceuticals ($INO) took a hit Tuesday on rumors that CEO Joseph Kim was "walking back expectations" for a Phase II study of DNA vaccine candidate VGX-3100 in women with cervical precancerous lesions. As TheStreet's Adam Feuerstein theorized, the company already has the data--and they don't look so good. "Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?" he asked. That question sent shares spiraling downward 13.36%, but Inovio refuted the claim. "There exists the prospect that our immunotherapy approach may eliminate the presence of HPV virus to minimize future recurrences," it said in a statement Wednesday. Report | More